Bank of New York Mellon Corp Raises Position in Illumina, Inc. (NASDAQ:ILMN)

Bank of New York Mellon Corp grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.8% during the fourth quarter, HoldingsChannel reports. The firm owned 3,402,057 shares of the life sciences company’s stock after purchasing an additional 27,618 shares during the quarter. Bank of New York Mellon Corp’s holdings in Illumina were worth $454,617,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. WCM Investment Management LLC lifted its stake in shares of Illumina by 26.6% during the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after purchasing an additional 867,673 shares during the period. Geode Capital Management LLC increased its holdings in shares of Illumina by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after buying an additional 48,018 shares during the last quarter. Primecap Management Co. CA increased its holdings in shares of Illumina by 3.6% during the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after buying an additional 87,599 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after buying an additional 625,245 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Illumina by 4.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock worth $164,334,000 after buying an additional 54,319 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $95.73 on Wednesday. The company has a market capitalization of $15.16 billion, a PE ratio of -12.46, a price-to-earnings-growth ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a one year low of $91.92 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The company’s fifty day moving average price is $126.02 and its 200 day moving average price is $133.80.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Piper Sandler upped their price objective on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Morgan Stanley lowered their price target on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Robert W. Baird increased their price target on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Finally, Guggenheim lowered their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.